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Objectives: Concise “synthetic” review of the state of the art of
management of acute ischemic stroke.
Data Sources: Available literature on PubMed.
Study Selection: We selected landmark studies, recent clinical
trials, observational studies, and professional guidelines on the
management of stroke including the last 10 years.
Data Extraction: Eligible studies were identified and results leading to guideline recommendations were summarized.
Data Synthesis: Stroke mortality has been declining over the past
6 decades, and as a result, stroke has fallen from the second to
the fifth leading cause of death in the United States. This trend may
follow recent advances in the management of stroke, which highlight the importance of early recognition and early revascularization.
Recent studies have shown that early recognition, emergency interventional treatment of acute ischemic stroke, and treatment in
dedicated stroke centers can significantly reduce stroke-related
morbidity and mortality. However, stroke remains the second leading
cause of death worldwide and the number one cause for acquired
long-term disability, resulting in a global annual economic burden.
Conclusions: Appropriate treatment of ischemic stroke is essential
in the reduction of mortality and morbidity. Management of stroke
involves a multidisciplinary approach that starts and extends beyond hospital admission. (Crit Care Med 2020; 48:1654–1663)
Key Words: cerebral edema; penumbra; secondary neuronal injury

T

reatment of acute ischemic stroke (AIS) consists of a
multidisciplinary approach that more than ever requires
the involvement of the critical care specialist. Before the
1990s, treatment options for AIS were limited and mainly focused on symptomatic management, secondary prevention, and
rehabilitation. Since then, the entire field was revolutionized
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by two major introductions. The first groundbreaking innovation that dramatically transformed acute stroke care on the
basis of a National Institutes of Neurological Disease and Stroke
(NINDS) landmark study was the Federal Drug Administration’s (FDA) approval of IV tissue plasminogen activator (IVtPA) in 1995 (1). IV-tPA remained the mainstay of treatment
for about 2 decades until 2015 when more sophisticated clinical trials showed robust outcomes for endovascular therapy
(EVT) (2). In the ICU, additional strategies aimed at optimizing
patient’s physiology can interface between triage and/or revascularization and discharge to rehabilitation.

EARLY DETECTION
Ischemic stroke can occur both in the community and in the hospital and must be recognized by bystanders and/or providers. Early
recognition activates a stroke-specific chain of survival (Table 1)
(3). Stroke is a clinical diagnosis and several features of the patient’s
clinical presentation can be used to identify stroke patients (Table
2). Emergency Medical Systems are key in detection, triaging, and
transport of stroke patients to receiving facilities.

PREHOSPITAL MANAGEMENT
Workflows and organized systems of care can efficiently reduce
delays in time to treatments (Fig. 1). With the deployment of
mobile stroke units (MSUs) equipped with CT scanners and
telemedicine links, recognition of patients and administration
of treatments may be more precise and efficient. Recent studies have shown that the implementation of MSUs has led to
higher rates and reduced the time to IV-tPA administration and
door-to-needle time compared with regular ambulance transports to emergency departments (EDs) (4–8). In theory, initiation of therapies for intracerebral hemorrhage (ICH) such as
blood pressure control and reversal of anticoagulation may also
be implemented at the prehospital setting. In addition to clinical
examination with conventional scales such as the Neurological
Institutes of Health Stroke Scale (NIHSS), several prehospital
scales and prompt recognition of severe strokes with large vessel
occlusions (LVOs) have successfully been validated (Table 3) (9).

EMERGENCY DEPARTMENT, STROKE
TEAMS, AND STROKE CODE
A stroke team can provide around the clock services for
patients with stroke. Such team consists of physicians with
November 2020 • Volume 48 • Number 11
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expertise in emergency medicine, vascular neurology/neurosurgery, and radiologists; advance care providers, nurses,
clinical pharmacists, therapists, and technicians; and laboratory personnel (10). In the ED, the efficiency and accuracy of
recognition of stroke syndromes can be performed with telemedicine (11). In the Stroke Team Remote Evaluation Using a
Digital Observation Camera (STRokE-DOC) study, two-way
audiovisual consultation was superior to telephone-based consultation in accurately identifying stroke patients, yielding a
higher rate of IV-tPA administration with similar proportion
in ICH but without effect on overall functional outcome (11).
In the new era of recanalization for AIS with LVO (12), telemedicine systems have assisted in improving the recognition
of stroke patients in need of endovascular therapies yielding to
better functional outcomes and quality of life (13–16).

NEUROIMAGING
Conventional noncontrast CT can be implemented at the prehospital level in specialized MSUs. A noncontrast CT scan has
enough sensitivity to exclude hemorrhagic stroke such as subarachnoid hemorrhage or ICH. The Alberta Stroke Program
Early CT Score (ASPECTS) was designed to determine middle
cerebral artery (MCA) infarct severity using a noncontrast
head CT scan. One point gets subtracted from the maximum
score of 10 for any sign of early ischemia in each of the 10 predefined zones (ranges 0–10) (17) (Fig. 2). A patient with a
high Rapid Arterial Occlusion Evaluation/NIHSS and normal
looking brain or ASPECTS greater than 6 (Fig. 2A) means that
infarction may not have set in and that revascularization strategies may be implemented. Early signs of infarction on CT or
lower ASPECTS are usually associated with poor prognosis and
hemorrhagic conversion (Fig. 2B). Timing to CT and reporting
of preliminary data should be under 20 minutes according to
current guidelines. A CT-angiography (CT-A) can effectively
detect LVO and provide useful information about the patient’s
vascular anatomy and stroke etiology (Fig. 3) (18). Based on its
rapid acquisition, many institutions now incorporate CT-perfusion (CT-P) technology to assess cerebral blood flow (CBF)
by quantitative analysis of thresholds in time-to-maximum
(T-max) transit and cerebral blood volumes. Quantification of
ischemic “core” (CBF < 30%) and estimation of “penumbra”
or tissue at risk (T-max > 6 s) can provide immediate information for treatment decision-making. Clinical trials have shown
that perfusion mismatch ratios of core/penumbra greater than
1.8 may indicate the eligibility for EVT (Fig. 4) (19, 20). CT-P
thresholds predicting infarction depend on the time from
stroke symptom onset to imaging, time from imaging to reperfusion, and the quality of reperfusion (21). To this end, a process that includes advanced imaging with CT-A/CT-P or MRI
should not delay IV thrombolysis or EVT.

TABLE 1.

The 8 D’s of Stroke Care

Detection: Involves recognizing the signs and symptoms of
an acute stroke (BEFAST, Table 2)
Dispatch: Activation of emergency medical services. In most
cases, this involves calling 911 or a stroke team
Delivery: Means prompt transport of the patient to a hospital,
preferably a stroke center or to a setting in the hospital for
further evaluation by a stroke team
Door: This refers to the arrival of the patient at the ED. According to recommendations from the National Institute of
Neurological Disorders and Stroke, an assessment should
be completed by an ED physician within 10 min of arriving in
the ED
Data: Data collection includes results from laboratory tests and
both a physical and a neurologic examination (Neurological
Institutes of Health Stroke Scale)
Decision: Information, such as the type of stroke, last seen
normal, and time from onset of symptoms, is considered before a treatment decision is made
Drug/device: Fibrinolytic therapy should be administered within
4.5 hr of the onset of symptoms. Even if the patient is not a
candidate for fibrinolysis, they may still qualify for endovascular therapy to remove mechanically a clot
Disposition: It is recommended that patients are admitted to
an ICU or stroke unit within 3 hr of arrival in the ED
ED = emergency department.
See Table 2 for BEFAST expansion.

IV Thrombolysis
The first landmark clinical trial that demonstrated the safety
and efficacy of IV-tPA in 1995 transitioned the treatment for
AIS from being purely symptomatic to a highly time-sensitive
matter. It shows that if IV-tPA is administered within the first
3 hours of symptom onset, patients are at least 30% more
likely to have only minimal or no disability on the 90-day
mark. Mortality difference between IV-tPA and placebo
group was nonsignificant despite an increase in symptomatic
hemorrhages in the treatment group (1). Although IV-tPA
was the only AIS treatment until recently, the use of IV-tPA
has been as low as 3.2–5.2% of all AIS patients in the United
States (22). One major reason for the low treatment rate is
the limited time window for IV-tPA. Based on the European
study Thrombolysis with Alteplase 3 to 4.5 Hours after Acute
TABLE 2.

BEFAST, Detection of Stroke

Balance, acute or sudden onset of loss of balance or
coordination
Eyes, blurred or unclear vision, double vision, and gaze preference
Facial weakness or facial asymmetry

REVASCULARIZATION

Arm and/or leg weakness

The primary goal of advanced stroke management is revascularization and limitation of secondary neuronal injury. IV
thrombolysis and EVT are now available for selected patients.

Speech difficulty/slurring of speech

Critical Care Medicine

Time is brain, time to activate stroke system and stroke clock
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by Perfusion Imaging up to 9
Hours after Onset of Stroke
(EXTEND) clinical trial, CT-P
imaging was used to assess the
eligibility for IV-tPA and suggested that the efficacy and
safety of IV-tPA can extend up
to 9 hours and that revascularization can extend up to 24
hours (27).
Tenecteplase, a newer thrombolytic agent with high fibrinogen specificity and long
half-life, allowing it to be given
as a single bolus, had promising results in recent clinical
trials. The Tenecteplase versus
Alteplase before Thrombectomy
for Ischemic Stroke (EXTENTIA-TNK) trial demonstrated
that tenecteplase administration
Figure 1. Organization of stroke centers. EVT = endovascular therapy, IV tPA = IV tissue plasminogen activator.
resulted in a higher reperfusion
rate and a better functional outIschemic Stroke (ECASS-3), the American Heart Associa- come than alteplase in patients with AIS eligible for EVT (28, 29).
tion/American Stroke Association (AHA/ASA) extended the Tenecteplase appears to be as efficacious, with a similar side-effect
IV-tPA window from 3 to 4.5 hours in 2009 with additional profile as alteplase when used in patients without LVO (30, 31).
exclusion criteria (22–24). This extension increased the utili- However, at this time, tenecteplase is not FDA-approved for IV
zation of IV-tPA by up to 20% (25).
thrombolysis in AIS patients and does not have the same level of
Recently, clinical trials suggested that imaging rather than recommendation by the AHA/ASA as alteplase. This could exknown time of onset (last seen normal) can guide clinicians to
plain why many institutions have not adopted tenecteplase as a
treat patients using the time discrepancies of acute stroke show- thrombolytic for AIS.
ing. Data from the European multicenter clinical trial MRIEndovascular Therapy
Guided Thrombolysis for Stroke with Unknown Time of Onset
The FDA approval of IV-tPA has innovated the entire field of
(WAKE-UP) suggest that almost 50% of wake-up strokes and
emergency neurology. However, up to 69% of stroke patients
daytime strokes of unknown onset are IV-tPA candidates when
MRI criteria is used (26). However, cost, time spent in metal are ineligible to receive IV-tPA due to delayed hospital presenscreening, and often far distance to the scanner are clear lim- tation (32, 33). Over the last 3 years, the time window for AIS
itations to its implementation. In the Thrombolysis Guided treatment has expanded thanks to EVT and has provided physicians with a stronger therapeutic arsenal. The success of EVT
is measured by the degree or quality of revascularization. The
TABLE 3. Rapid Arterial Occlusion
Thrombolysis in Cerebral Infarction (TICI) scale is a tool to
Evaluation Scale
standardize the different degrees of reperfusion ranging from no
perfusion (TICI 0) to complete perfusion (TICI 3) (Table 4) (34).
Facial palsy: Absent (0), mild (1), and moderate (2)
TICI scores of 2B to 3 are usually regarded as successful reperfuArm motor impairment: Normal to mild (0), moderate (1), and
sion. Previous studies failed to show improved results with EVT
severe (2)
and diminished the initial optimism regarding intervention for
Leg motor impairment: Normal to mild (0), moderate (1), and
AIS (35–37). However, the study design of those clinical trials
severe (2)
was criticized for not requiring the image proof of LVO, using
older technology for clot retrieval, and having prolonged stroke
Head/gaze deviation: Absent (0) and present (1)
to puncture times. Since 2015, multiple trials have shown the efAphasia: Performs tasks correctly (0), performs one task corficacy of EVT in addition to standard medical care in improving
rectly (1), and performs neither task (2)
the overall outcome of AIS patients with proximal MCA or inAgnosia: Recognizes his/her arm and deficit (0), does
ternal carotid artery (ICA) occlusion when EVT was performed
recognize his/her arm but not or deficit (1), and does not
within either 6 hours (20, 38–41), 8 hours (42), or 12 hours (43)
recognize his/her arm or deficit (2)
of symptom onset. A pooled meta-analysis demonstrated that
A score of ≥ 5, indicates higher likelihood of large vessel occlusion with 85%
sensitivity and 68% specificity (9).
modern EVT more than doubles the odds of a better functional
1656
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further clinical trials are necessary to investigate the efficacy
of EVT in LVO presenting as
minor strokes (NIHSS < 5).

ICU MANAGEMENT

Figure 2. Alberta Stroke Program Early CT Score (ASPECTS). Scoring for each of the 10 zones. Each zone is
graded either 1 (normal) or 0 (abnormal). The sum of all zones gives the ASPECTS. A, Normal looking brain with
ASPECTS = 10. B, Brain with ischemic changes and ASPECTS less than 6. C = caudate, Ic = internal capsule,
In = insular cortex, M = middle cerebral artery, P = putamen.

outcome compared with standard therapy alone without any significant difference in the mortality or risk of parenchymal hemorrhage at 90 days (2). Of 100 patients treated with EVT, 38 had
a better functional outcome than the standard medical care. The
number-needed-to-treat (NNT) for at least one patient to have
a 1-point reduction on the modified Rankin Scale (mRS) is 2.6.
The benefit of EVT remains substantial when only looked at the
subset of patients that received IV-tPA prior to thrombectomy,
and therefore, EVT should still be pursued after IV-tPA administration. It is also suggested that EVT should not be withheld only
on the basis of age, and patients older than 80 years may also benefit from EVT (12). Two recent clinical trials showed that the time
window can further be extended to 24 hours postsymptom onset
if there is either mismatch between the clinical deficit and the infarct size or perfusion mismatch on imaging (19, 44). These trials
are moving us away from an arbitrary clock time limit and transforming the way we think of stroke and the “biological clock.”
In most of these trials, the mean NIHSS was 16 or greater and
Critical Care Medicine

Oxygenation and
Ventilation
Supplemental oxygen may be required if a patient’s saturation is
less than 94%. Rapid neurologic
deterioration and ensuing loss
of consciousness with impairment of reflexes that maintain
the airway mandate definitive
airway control. Failure to recognize imminent airway loss may
result in complications such as
aspiration, hypoxemia, and hypercapnia, which may result in
secondary neuronal injury. Hyperbaric oxygen was shown to
either have no effect or be harmful in AIS patients and should be
avoided (45). For those critically
ill AIS patients with respiratory
failure and failure to wean off
the ventilator, long-term tracheostomy may be required. The
benefit of early tracheostomy is
debatable but currently being
studied under the Early Tracheostomy in Ventilated Stroke
Patients 2 (SETPOINT-2) prospective clinical trial (ClinicalTrials.gov: NCT02377167).

Blood Pressure
As part of cerebral autoregulation, blood pressure is commonly elevated during the acute phase of AIS, maximizing
perfusion in the ischemic areas (46, 47). However, severe hypertension can lead to hemorrhagic transformation of the
infarct, hypertensive encephalopathy, as well as cardiopulmonary and renal complications. Current AHA/ASA guidelines recommend permissive hypertension with a blood
pressure goal of less than or equal to 220/120 mm Hg for
the first 24–48 hours. Yet, these blood pressure variables
only apply if the patient is not undergoing any acute intervention such as IV-tPA or EVT. If the patient receives IVtPA, the risk of hemorrhagic transformation increases and
the blood pressure should be lowered to less than or equal
to 185/110 mm Hg prior to IV-tPA administration and to
less than or equal to 180/105 mm Hg once IV-tPA has been
given (48). Reperfusion injury and hemorrhagic transformation are of concern in the case of EVT; thus, blood pressure
www.ccmjournal.org
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Glycemic Control
Evidence indicates that persistent in-hospital hyperglycemia
during the first 24 hours after AIS is associated with worse
outcomes compared with normoglycemia due to multiple potential mechanisms, such as endothelial dysfunction, increased
oxidative stress, and impaired fibrinolysis. However, in the
NINDS funded Stroke Hyperglycemia Insulin Network Effort
(SHINE) clinical trial, an intensive IV insulin protocol to
achieve a systemic glucose between 80 and 130 mg/dL was not
associated with favorable outcomes at 90 days compared with a
standard regimen of insulin in a “sliding-scale” fashion to keep
the glucose between 80 and 180 mg/dL (52). The intensive insulin protocol was associated with significant hypoglycemic
events and a higher level of care. To this end, it is reasonable to
treat hyperglycemia to achieve blood glucose levels in a range
of 140–180 mg/dL and to monitor closely to prevent hypoglycemia in patients with AIS.

Figure 3. CT-angiography demonstrating an abrupt occlusion of the
patient’s left middle cerebral artery (arrow). L = left, R = right.

must be closely monitored during and after EVT. A retrospective cohort study suggests maintaining an MAP goal of
70–90 mm Hg during EVT to improve functional outcome
(49). The current AHA/ASA guidelines recommend a postEVT blood pressure of less than or equal to 180/105 mm Hg
(48). However, that guideline does not consider the degree
of reperfusion achieved during EVT. In patients with successful recanalization, defined as TICI 2b and TICI 3, the
optimal postoperative blood pressure might be lower than
that stated by the guidelines, to minimize the risk of reperfusion injury and ICH. A moderate blood pressure control
with a systolic blood pressure goal less than or equal to
160 mm Hg was shown to reduce the incidence of ICH and
mortality, if successful EVT was achieved (50). Anadani et
al (51) demonstrated that a postprocedural blood pressure
range from 121 to 140 mm Hg was associated with improved
functional outcome compared with higher blood pressure, if
the patients had successful recanalization. Given these data,
it appears that blood pressure after EVT should be individualized based on the degree of recanalization.
Hypotension and hypovolemia should be avoided and
corrected in patients with AIS. Etiologies for hypotension
should ideally be sorted out with noninvasive modalities
such as point-of-care ultrasound. While correcting hypovolemia, hypotonic solutions should be avoided due to the
risk of increased edema formation. The usefulness of druginduced hypertension is not well established, so the randomized multicenter Safety and Efficacy of Therapeutic INduced
HYPERTENSION in Acute Non-cardioembolic Ischemic
Stroke (SETIN-HYPERTENSION) clinical trial (ClinicalTrials.
gov: NCT01600235) aims at determining the safety and efficacy of phenylephrine in patients with noncardioembolic
stroke.
1658
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Cerebral Edema
Large infarcts of the MCA or ICA are associated with high
morbidity rates of up to 80%. Patients with large hemispheric
infarcts (LHIs) are at increased risk of cerebral edema and fast
neurologic deterioration that led to the term “malignant MCA
infarction”(MMI) (53). Hypodensity seen in more than 50%
of the MCA territory (Fig. 2B) or an infarct volume of greater
than 145 cc within 14 hours of ictus are the most reliable predictors for a malignant course with increased intracranial pressure, herniation, and need for decompressive hemicraniectomy
(DHC) (54). The ultimate intervention to alleviate increased
intracranial pressure and avoid herniation in LHI with significant edema is surgical decompression with DHC. Three European clinical trials assessed the benefit of DHC in patients
60 years and younger (55–57). A pooled analysis of these trials
showed that DHC does not only reduce mortality by 50% but
also improve long-term functional outcome (58). The NNT
to avoid a death is 2 (mRS = 6), whereas the NNT to avoid
death and the most severe to moderately severe disability is 4
(mRS = 4–6). The proportion of patients alive with minimalto-moderate disability (mRS = 0–3) was increased from 21%
to 43%. Viewed another way, DHC resulted in a 49% absolute
risk reduction in death, and an absolute increase in the proportion of patients rated as mRS = 2 of 12%, mRS = 3 of 10%, and
mRS = 4 of 29% (58).
The DEcompressive Surgery for the Treatment of malignant INfarction of the middle cerebral arterY (DESTINY-II)
clinical trial assessed the outcome of DHC in patients older
than 60. It demonstrated that DHC increases the probability of
survival, but most survivors had significant disabilities (mRS
= 4–5) (59). In all these trials, DHC was performed within 48
hours, and currently, there is no indication for a “wait and see
strategy” (e.g., waiting for neurologic deterioration or radiographic midline shift). However, the ideal timing of DHC is
still unclear and more data including standardized medical
management are necessary. Furthermore, it remains debatable
what the definition of a favorable functional outcome is and
what degree of disability is regarded as acceptable. Additional
November 2020 • Volume 48 • Number 11
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Figure 4. Mismatch ratio analysis of cerebral blood flow (CBF) by quantitative analysis of thresholds in time-to-maximum (T-max) to transit in a patient
with a right middle cerebral artery occlusion. CBF in dark gray and T-max in light gray. A ratio of greater than 1.8 usually indicates eligibility for endovascular therapy. RAPID = rapid processing of perfusion and diffusion image analysis system.

surgical interventions that may be entertained in critically ill
AIS patients are external ventricular drainage for the management of hydrocephalous and suboccipital craniectomy for
posterior fossa/cerebellar infarcts with life-threatening cerebral edema.
In contrast to the three European DHC trials, the NINDS
funded clinical trial Hemicraniectomy and durotomy upon deterioration from infarction-related swelling trial (HeADFIRST)
did not find a mortality or morbidity benefit of DHC over a
standardized medical treatment approach, which included
normoglycemia (glucose < 200 mg/dL), permissive hypernatremia (sodium < 155 mEq/dL), and hyperosmolar therapy
(60). This raises the question if a conservative approach should
be trialed prior to DHC.
Data on the use of hyperosmolar therapy in MMI are scarce
and the evidence for reducing ICP is mainly extrapolated from
the traumatic brain injury literature. Despite the lack of clear
evidence in MMI, hyperosmolar therapy with mannitol or
hypertonic saline (HTS) has been proposed to reduce cytotoxic edema (61, 62). There is no definitive data whether one
Critical Care Medicine

hyperosmolar agent is superior to the other, and the choice
can be guided by their individual side effects. Potential complications of HTS use are fluid overload, pulmonary edema,
hypokalemia, cardiac arrhythmias, hyperchloremic metabolic
acidosis, acute kidney injury, and dilutional coagulopathy
(63, 64). To avoid rebound edema, HTS should be gradually
tapered and the serum sodium level should never be allowed to
drop more than 10–12 mEq/L over 24 hours (63, 65). Potential
complications of mannitol include acute kidney injury, hypotension due to diuresis, rebound ICP, electrolytic imbalance
(hypo-/hypernatremia), and acid/base disturbances.
Glyburide, an IV sulfonylurea has been proposed as a potential agent for the management of cerebral edema due to its
ionic properties at the sulfonylurea receptor-1-transient receptor potential melastatin-4 channel in neurons, astrocytes,
and endothelium. The recent Safety and efficacy of intravenous
glyburide on brain swelling after large hemispheric infarction
(GAMES-RP) clinical trial demonstrated a substantial reduction in cerebral edema and midline shift without an impact
on the outcomes (66). The industry-sponsored Phase 3 Study
www.ccmjournal.org
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TABLE 4.

Scale

Thrombolysis in Cerebral Infarction

Grade

Radiographic Features

0

No perfusion beyond the point of occlusion

1

Penetration with minimal perfusion. Contrast passes
the obstruction but fails to visualize the entire
cerebral bed beyond the point of obstruction

2

Partial perfusion. Contrast passes the obstruction
and visualized the cerebral bed past the obstruction. However, flow of contrast in the distal bed
is slower than other, nonobstructed vessels

2A

Only < 2/3 of entire vascular territory is visualized

2B

Complete visualization of the vascular territory but
with slower filling than normal

3

Complete perfusion. Entire vascular territory is
visualized with normal flow

Higashida et al (34).

to Evaluate the Efficacy and Safety of Intravenous BIIB093
(Glibenclamide) for Severe Cerebral Edema Following Large
Hemispheric Infarction (CHARM) clinical trial testing a similar hypothesis with the sulfonylurea glibenclamide is underway (ClinicalTrials.gov: NCT0286495).
Fever and Targeted Temperature Modulation
Observational studies have demonstrated the detrimental
effects of fever on every outcome measure after stroke (67,
68). It appears that the effect of fever (temperature core [Tc]
> 37.5°C) is pertinent to severely brain injured patients in
the ICU (69). Clinical studies have shown the potential effect
of therapeutic hypothermia (Tc, 34–35°C) for the management cerebral edema and intracranial hypertension. One
study assessed the effect of targeted temperature modulation on mortality and neurologic outcome in patients with
LHIs but failed to show a difference with a trend toward better functional outcome (70). Recently, the largest randomized clinical trial on therapeutic hypothermia after ischemic
stroke European multicenter, randomized, phase III clinical
trial of therapeutic hypothermia plus best medical treatment
vs. best medical treatment alone for acute ischemic stroke
(EURO-HYP) was stopped on the basis of futility. Similarly,
the DEcompressive surgery Plus hypoTHermia for SpaceOccupying Stroke (DEPTH-SOS) study, using therapeutic hypothermia and DHC after LHIs, was terminated early on the
basis of harm in the therapeutic hypothermia arm (71). The
ongoing Impact of Fever Prevention in Brain Injured Patients
(INTREPID) randomized clinical trial is testing the hypothesis that early fever prevention to achieve normothermia
(Tc = 37°C) after stroke is associated with improved outcomes
(ClinicalTrials.gov: NCT02996266). Although there is paucity
of high-quality data in support of fever control after ischemic
stroke, it is recommended that patients with severe brain injury and fever refractory to medical therapy receive some degree of fever prevention while in the ICU (72).
1660
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Rehabilitation
Early mobilization is thought to be of great importance in
order to maximize functional recovery and independence after
AIS. Animal models have shown that neuroplasticity and cortical reorganization, promoting functional improvement, peak
7–14 days after stroke and last for about 1 month (73). Early
rehabilitation is thought to enhance further this dynamic poststroke phase and help patients to gain compensatory mechanisms for remaining disabilities. Data show that even in ICU
patients, early rehabilitation and intensity of rehabilitation
sessions were associated with a better functional outcome
(74). Yet, the optimal intensity and timing of early mobilization remain uncertain. The phase-III A Very Early Rehabilitation Trial after stroke (AVERT) clinical trial demonstrated that
very early mobilization (< 24 hr after stroke) with frequent and
prolonged rehabilitation sessions resulted in reduced favorable
outcome. However, the dose-response analysis showed that
short and frequent mobilizations may be beneficial early after
acute stroke, whereas prolonged out-of-bed sessions reduce
the odds of a good outcome (75). Furthermore, randomized
controlled trials are needed to clarify those uncertainties.
Nutrition
As in the case with all critically ill neurologic patients, enteral feeding should be started within 48 hours to avoid protein catabolism and malnutrition. A small-bore nasoduodenal
feeding tube may reduce the risk of aspiration events. Assessment of speech and swallowing function is imperative in AIS
patients to determine the need for long-term enteral nutrition
with percutaneous enteric gastrostomy.
Risk Factor Modification (Secondary Prevention)
Classification of AIS subtype/etiology is based on the definitions used in the multicenter Trial of Org 10172 in Acute
Stroke Treatment and include the following: 1) large-artery
atherosclerosis, 2) cardioembolism, 3) small-vessel occlusion,
4) stroke of other determined etiology, and 5) stroke of undetermined etiology (cryptogenic) (76). A thorough workup
consisting of vascular imaging, MRI, transthoracic echocardiogram with bubble assessment (for shunt evaluation),
lipid panel, and hemoglobin A1C, among others, is required
to determine the underlying etiology and tailor the appropriate secondary stroke prevention. Antiplatelet therapy is
an important cornerstone of treatment for the prevention of
stroke and transient ischemic attacks (TIAs). Aspirin is the
most commonly used agent, since it is relatively safe, cheap,
and widely available. It reduces the risk of recurrent stroke
within the acute phase of 2–4 weeks post-AIS if administered
within 48 hours of onset (77, 78). A meta-analysis of 16 secondary prevention trials concluded that aspirin reduces the
risk of recurrent ischemic stroke by 22% and has the strongest
effect in the early weeks after AIS (79, 80). The P2Y12 inhibitor clopidogrel is another commonly used antiplatelet agent
in AIS. The Clopidogrel with Aspirin in Acute Minor Stroke
or Transient Ischemic Attack (CHANCE) trial, a study with
primary Asian ethnicity, demonstrated a reduction of 90-day
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stroke incidence after minor strokes (NIHSS < 4) or TIAs with
the combination therapy aspirin and clopidogrel (dual antiplatelet therapy) for 21 days poststroke when compared with
aspirin alone, without demonstrating an increase in hemorrhages (81). The American Clopidogrel and Aspirin in Acute
Ischemic Stroke and High-Risk TIA (POINT) trial was able
to reproduce those results in a more ethnically diverse cohort (82). Finally, cardioembolic strokes that account for up
to 40% may warrant treatment with full anticoagulation to
prevent recurrence. However, depending on the infarct size,
full anticoagulation could result in hemorrhagic transformation in the immediate poststroke period. For these patients, an
initial strategy of antiplatelet therapy bridging to full anticoagulation within 10–14 days of stroke is widely accepted and
based on clinical trials that demonstrated the risk of stroke
recurrence within this time frame is minimal (48, 83, 84). In
certain patients with embolic strokes of undetermined source,
long-term cardiac monitoring may be indicated to increase
the yield of diagnosing paroxysmal atrial fibrillation (85).
Statins are the drug of choice for dyslipidemia, which is an
important risk factor for atherosclerotic disease. In recent years,
studies showed that statins have a pleiotropic effect beyond
lowering cholesterol including being antithrombotic, anti-inflammatory, and endothelial protective (86). The The Stroke
Prevention by Aggressive Reduction of Cholesterol Levels
(SPARCL) clinical trial assessed the effect of statins on secondary stroke prevention and demonstrated that high-intensity
atorvastatin reduces both fatal and nonfatal stroke recurrence
with the highest effect in the carotid stenosis group. The study
included patients with small-vessel occlusion, large vessel atherosclerosis, and unknown etiology excluding cardioembolic
strokes (87). Recent clinical trials suggest that cholesterol lowdensity-lipoprotein level ~70 mg/dL is optional to decrease
stroke recurrence (88). Although some studies showed an
increased risk of ICH with statin therapy (89, 90), other pooled
analyses failed to demonstrate that relationship (91, 92).

CONCLUSIONS
Over the last few decades, multiple new innovations have
introduced a new era of vascular neurology and included more
patients for acute treatment, leading to improved outcome.
Despite these groundbreaking changes, the constant decline in
stroke mortality has slowed down and even reversed in several states of the United States (93). One of the reasons for this
trend is the rising number of patients with stroke risk factors
like diabetes, hypertension, and hyperlipidemia. In the future,
the focus should shift more toward patient education and prevention in order to reduce the incidence of stroke leading to
severe disability or death.
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